Literature DB >> 22374236

Integrase-independent HIV-1 infection is augmented under conditions of DNA damage and produces a viral reservoir.

Hirotaka Ebina1, Yuka Kanemura, Yasutsugu Suzuki, Kozue Urata, Naoko Misawa, Yoshio Koyanagi.   

Abstract

HIV-1 possesses a viral protein, integrase (IN), which is necessary for its efficient integration in target cells. However, it has been reported that an IN-defective HIV strain is still capable of integration. Here, we assessed the ability of wild type (WT) HIV-1 to establish infection in the presence of IN inhibitors. We observed a low, yet clear infection of inhibitor-incubated cells infected with WT HIV which was identical to cells infected with IN-deficient HIV, D64A. Furthermore, the IN-independent integration could be enhanced by the pretreatment of cells with DNA-damaging agents suggesting that integration is mediated by a DNA repair system. Moreover, significantly faster viral replication kinetics with augmented viral DNA integration was observed after infection in irradiated cells treated with IN inhibitor compared to nonirradiated cells. Altogether, our results suggest that HIV DNA has integration potential in the presence of an IN inhibitor and may serve as a virus reservoir. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374236     DOI: 10.1016/j.virol.2012.02.004

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Authors:  Benjamin Trinité; Eric C Ohlson; Igor Voznesensky; Shashank P Rana; Chi N Chan; Saurabh Mahajan; Jason Alster; Sean A Burke; Dominik Wodarz; David N Levy
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

2.  Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.

Authors:  Janani Varadarajan; Mary Jane McWilliams; Stephen H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

3.  DNA damage promotes herpes simplex virus-1 protein expression in a neuroblastoma cell line.

Authors:  Ketna Volcy; Nigel W Fraser
Journal:  J Neurovirol       Date:  2013-01-26       Impact factor: 2.643

Review 4.  Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.

Authors:  C W Peterson; P Younan; K R Jerome; H-P Kiem
Journal:  Gene Ther       Date:  2013-01-31       Impact factor: 5.250

5.  DNA damage enhances integration of HIV-1 into macrophages by overcoming integrase inhibition.

Authors:  Takayoshi Koyama; Binlian Sun; Kenzo Tokunaga; Masashi Tatsumi; Yukihito Ishizaka
Journal:  Retrovirology       Date:  2013-02-21       Impact factor: 4.602

6.  Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors.

Authors:  Daniel C Farley; Laura McCloskey; Barbara A Thorne; Semih U Tareen; Christopher J Nicolai; David J Campbell; Richard Bannister; Hannah J Stewart; Laura Je Pearson; Bentley J Moyer; Scott H Robbins; Leah Zielinski; Tae Kim; Pippa A Radcliffe; Kyriacos A Mitrophanous; Wayne R Gombotz; James E Miskin; Brenna Kelley-Clarke
Journal:  Mol Ther Methods Clin Dev       Date:  2015-05-13       Impact factor: 6.698

7.  A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector.

Authors:  Hirotaka Ebina; Yuka Kanemura; Naoko Misawa; Tetsushi Sakuma; Tomoko Kobayashi; Takashi Yamamoto; Yoshio Koyanagi
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

8.  Insight into the ERVK Integrase - Propensity for DNA Damage.

Authors:  Samantha Bray; Matthew Turnbull; Sherry Hebert; Renée N Douville
Journal:  Front Microbiol       Date:  2016-12-01       Impact factor: 5.640

9.  Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus.

Authors:  Hirotaka Ebina; Naoko Misawa; Yuka Kanemura; Yoshio Koyanagi
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

Review 10.  Gene therapy on the move.

Authors:  Kerstin B Kaufmann; Hildegard Büning; Anne Galy; Axel Schambach; Manuel Grez
Journal:  EMBO Mol Med       Date:  2013-09-17       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.